Premium
Bisphosphonate therapy start may transiently increase the risk of tendon rupture in patients with glucocorticoid co‐medication: a population‐based observational study
Author(s) -
Spoendlin Julia,
Meier Christian,
Jick Susan S.,
Meier Christoph R.
Publication year - 2016
Publication title -
pharmacoepidemiology and drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.023
H-Index - 96
eISSN - 1099-1557
pISSN - 1053-8569
DOI - 10.1002/pds.4042
Subject(s) - medicine , bisphosphonate , glucocorticoid , prednisone , odds ratio , pharmacoepidemiology , population , medical prescription , osteoporosis , pharmacology , environmental health
Purpose The effect of bisphosphonates on extra‐osseous tissue is rarely investigated. We performed an exploratory analysis on the association of new bisphosphonate use and incident tendon rupture in patients with or without oral glucocorticoid co‐medication. Methods We conducted a matched case–control study using data from the UK‐based Clinical Practice Research Datalink. Cases were patients aged 30–89 years with an incident diagnosis of Achilles or biceps tendon rupture between 1995 and 2013. We compared new oral bisphosphonate use between cases and controls with or without oral glucocorticoid co‐medication, by timing (last prescription